Latest 10-K annual reports

DiaMedica Therapeutics' 2025 annual report details progress in DM199 clinical trials for preeclampsia and stroke, alongside financial losses and enrollment challenges.

VanEck Avalanche ETF's 2025 annual report details significant asset growth and operational setup, alongside extensive disclosures on the inherent volatility and regulatory challenges of the digital asset market.

Firsthand Technology Value Fund, Inc. reported a significant net loss for 2025, with total liabilities exceeding assets, raising substantial doubt about its ability to continue as a going concern.

Chase Packaging Corporation, a shell company, reported a net loss of $76,742 for fiscal year 2025 and extended the expiration date of its outstanding warrants to March 7, 2029, as it continues to seek a merger or acquisition.

RenovoRx, a life sciences company, reported $1.1 million in RenovoCath sales for 2025 and continued progress in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer.

Quest Patent Research Corporation reported a significant net loss of $8.5 million and no revenue for the year ended December 31, 2025, raising substantial doubt about its ability to continue as a going concern.

CXApp Inc. reported a 36% revenue decline and a $13.473 million net loss for 2025, while facing a Nasdaq delisting notice for its stock price.

Jasper Therapeutics reports positive clinical data for briquilimab in mast cell diseases, but faces significant net losses and substantial doubt about its ability to continue as a going concern.

Lumexa Imaging posted 7.8% revenue growth to $1.023B in 2025, narrowed its net loss to $47.1M, raised $427M in its December IPO, and refinanced debt while flagging material weaknesses in internal controls.

Annexon posted a $206.7M 2025 net loss, filed an EMA MAA for GBS, guided to a 2026 U.S. BLA and GA Phase 3 topline in 4Q26, and added a new $150M ATM financing facility.

Array Digital Infrastructure filed a 10-K/A solely to include audited financials for its 5.5% Los Angeles SMSA Limited Partnership interest, plus auditor consent and updated CEO/CFO certifications, with no other changes to the original 10-K.

Transportation and Logistics Systems filed its 2025 10-K showing no operations, a going‑concern warning, heavy reliance on debt-for-equity swaps, and potential issuance of over 11B new shares via Series J preferred.

NewHydrogen reported a larger 2025 net loss, no revenue, and signaled a need for additional capital in the second half of 2026 while advancing its ThermoLoop green hydrogen program and patent portfolio.

PMV Consumer Acquisition Corp. filed its 2025 10-K showing no revenues, a small net loss, OTC Pink trading, tight cash burn, and continued pursuit of a business opportunity, primarily in consumer products.

Allarity Therapeutics cut operating losses, resolved SEC matters, and advanced its PARP/tankyrase inhibitor stenoparib with Fast Track status and new trials while maintaining $14.7M cash at year-end.

eXoZymes reported a wider 2025 net loss, sharply lower cash, and a going concern warning while advancing its NCT program and winning new grants.

Clinical-stage radiopharma Aktis Oncology reported a $63.7M 2025 net loss, strengthened liquidity with a $335.3M January 2026 IPO and Lilly collaboration, and guided cash runway into 2029 as it advances Nectin-4 and B7-H3 programs.

Byrna Technologies amended its FY2025 annual report to add Part III disclosures, detail leadership changes, executive pay, ownership, governance policies, and auditor fees, with no financial statements updated.

Newly public fuel distributor reported 2025 results, launched a $2.00/share annual dividend, and used ~$207M IPO proceeds to reduce debt.

First Keystone posted 2025 net income of $6.2 million and stronger margins, but nonperforming assets jumped and a material weakness in internal controls was disclosed.

REX American Resources posted higher FY2025 net income on 45Z clean fuel tax credits, maintained strong cash, accelerated buybacks, and advanced a major carbon sequestration plan amid permitting delays.

BNY Mellon reports no material servicing noncompliance for 2025, KPMG issues clean attestation, and no material legal proceedings are disclosed for GJT.

BNY Mellon reports full Regulation AB servicing compliance for STRATS Trust 2006-2, with KPMG issuing a clean attestation and no material issues.

STRATS Trust for Procter & Gamble Securities, Series 2006-1 (NYSE: GJR) reported no material servicing noncompliance for 2025, with KPMG issuing an unqualified attestation of BNY Mellon’s trustee activities.

The travel-focused SPAC reported $3.9M 2025 net income driven by trust interest, holds $206.4M in its trust, and has until Feb. 16, 2027 to complete a business combination.

The STRATS Trust for Wal-Mart Stores, Inc. Series 2005-4 reported clean depositor/trustee compliance for 2025 with monthly distributions disclosed via Form 8-K and no legal proceedings.

Routine 10-K confirms clean trustee and CPA attestations, with 2025 distributions reported for the U.S. Cellular-backed STRATS Trust.

Newly launched multi-asset crypto ETF EZPZ reports $10.2M AUM, -9.67% NAV return, and tight index tracking with a 0.19% sponsor fee.

Photozou Holdings grew FY2024 revenue but widened net losses, flagged going-concern risks, raised equity, took a high-cost short-term loan, and plans a 2026 short drama launch after moving to exit used camera sales in 2025.

Electro-Sensors delivered record 2025 revenue of $10.1 million with higher gross margins, while net income declined on increased operating costs and lower interest income.